Miracle cures are few and far between. The best one can hope for is partial relief. So it is with Sanofi’s consumer health split. The French pharma group’s sale of a majority 50 per cent stake in its Opella unit to Clayton Dubilier & Rice leaves all participants with some ills to address.
奇迹般的治疗方法少之又少。人们所能期待的最好结果也只是部分缓解。赛诺菲的消费者健康业务分拆也是如此。这家法国制药集团将其Opella部门50%的多数股权出售给Clayton Dubilier & Rice公司后，所有参与者都面临着一些亟待解决的问题。
您已阅读12%（415字），剩余88%（3051字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。